What subcutaneous peptide bioavailability actually measures
Bioavailability compares the total drug exposure after a non-intravenous dose, measured as the area under the plasma concentration curve, against the exposure from an intravenous dose of the same compound. An IV dose is defined as 100 percent bioavailable because it enters the bloodstream directly, with nothing lost along the way. Every other route, including subcutaneous injection, is scored against that reference.
A subcutaneous dose has to clear two hurdles an IV dose skips entirely. It has to move out of the interstitial tissue at the injection site and into a capillary or a lymphatic vessel, and it has to survive whatever proteases are present in that tissue while it waits. Either step can strip away a meaningful share of the dose before it reaches systemic circulation at all.
Why the absorption route changes how much peptide survives
Molecular size sets the transport path. Peptides and small proteins under roughly 16 kDa diffuse across capillary walls and enter the bloodstream more or less directly. Larger molecules are picked up by the lymphatic system instead, which drains more slowly and routes the peptide through lymph nodes, giving proteolytic enzymes another opportunity to break it down before it reaches systemic circulation.
Subcutaneous injection sidesteps first-pass hepatic metabolism entirely, since absorbed peptide reaches the bloodstream through capillaries or lymphatics rather than the portal vein that feeds the liver. That is one reason subcutaneous bioavailability numbers, even the lower ones, still tend to beat oral bioavailability for peptides that do not survive gastric and intestinal proteases well enough to need protection in the first place.
Presystemic degradation at the injection site is the other variable, and it is largely independent of what happens once the peptide reaches circulation. A compound with a short intrinsic plasma half-life is often just as vulnerable to the proteases sitting in subcutaneous interstitial fluid, so it can lose a comparable share of the dose before absorption finishes, separate from how fast it later clears from the blood.
What the absorption data shows
A 2021 survey in the Journal of Controlled Release (Zou et al., n=18 peptides and small proteins) pulled clinical pharmacokinetic data from FDA filings and the published literature for every peptide or small protein with data from more than one subcutaneous injection site. Nine of the eighteen, exactly half the set, showed measurably different absorption depending on which site was used. The compounds most sensitive to site were the ones absorbed fastest, with a time to peak concentration under two hours, or the ones with the highest apparent clearance.
Small, well-characterized peptide hormones sit at the high end of subcutaneous bioavailability. In a conscious pig model built to mimic human subcutaneous physiology, Radziuk and colleagues (1997, Diabetes, volume 46) measured total subcutaneous absorption of unmodified human insulin at 97 percent plus or minus 10 percent of the injected dose, with 90 percent absorbed within about three hours. That figure sits close enough to the intravenous reference that, once absorption finishes, subcutaneous human insulin behaves close to how an intravenous dose would.
Larger, engineered peptides absorb less completely. Novo Nordisk ran a phase 1 crossover trial specifically to establish subcutaneous semaglutide's absolute bioavailability against an intravenous reference dose (ClinicalTrials.gov NCT02231684, n=42 healthy subjects), and the labeling data that followed the trial put the figure at 89 percent. A separate phase 1 trial in 36 healthy Chinese subjects recorded a steady-state terminal half-life of 156 to 159 hours and a median time to peak concentration of 30 to 42 hours after subcutaneous dosing, the depot-plus-albumin-binding combination that makes once-weekly injection possible. The semaglutide research overview covers the mechanism and trial history in more depth.
The gap between routes widens once the gut is involved. A 2024 systematic review in Drug Design, Development and Therapy (Yang and Yang) reports oral semaglutide's bioavailability at 0.8 percent under the recommended dosing conditions, a small fraction of the subcutaneous figure. Gastric and intestinal proteases, combined with the general difficulty of a peptide crossing the gut wall intact, account for most of that gap.
Not every widely used research peptide has a formal subcutaneous bioavailability figure at all. The only published pharmacokinetic characterization of BPC-157, using intravenous and intramuscular dosing in rat and beagle dog models, put absolute bioavailability after intramuscular injection at 14 to 19 percent in rats and 45 to 51 percent in dogs (He et al., 2022, Frontiers in Pharmacology). Subcutaneous injection is the default route in most BPC-157 research protocols, but no equivalent subcutaneous figure has been published.
A protocol that treats subcutaneous and intramuscular bioavailability as interchangeable for this compound is working from an assumption, not a measurement. The BPC-157 research overview and the compound catalog entry cover the rest of the preclinical evidence.
Practical considerations for protocol design
A published subcutaneous bioavailability figure changes how a dose gets planned, not just how a plasma curve gets read afterward. A compound with 50 percent subcutaneous bioavailability delivers half the systemic exposure of the same nominal dose given intravenously, so a protocol that switches routes mid-study without adjusting the dose is comparing two different exposures under one label. The peptide dosing calculator converts a target concentration into a draw volume for a given vial strength, but it has no way to know a compound's bioavailability fraction; that number has to come from the published literature for the specific peptide and route in use.
The condition of the reconstituted solution before injection also affects the number that eventually shows up in a study. A peptide that has already started to degrade in solution, through oxidation, aggregation, or a pH shift, presents a smaller intact dose at the injection site regardless of what the original bioavailability study measured on a fresh sample. Confirming solution clarity and correct storage temperature before drawing a dose rules out a source of variability that has nothing to do with the absorption route itself.
Handling subcutaneous bioavailability in a tropical research setting
Subcutaneous absorption studies are run under controlled laboratory conditions, typically standard room temperature or vivarium housing, not the ambient heat of a bench in Bali or Jakarta. A reconstituted peptide solution held above its recommended 2 to 8 degrees Celsius storage range degrades faster than the sample used in the original pharmacokinetic trial, and a degraded vial does not deliver the bioavailability the published study reported, no matter how carefully the injection itself is performed.
Cold-chain handling from the point of import through the point of injection matters more in a tropical climate than in the temperate settings where most peptide pharmacokinetic trials are conducted. Checking a courier's cold-chain record and inspecting vial appearance before reconstitution are two checks that catch a compromised vial before it changes a study's absorption numbers.